Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy

• Published in: Journal of Nuclear Medicine Vol. 62; no. 10; pp. 1475 - 1481
• Main Authors: Guzik, Patrycja, Fang, Hsin-Yu, Deberle, Luisa M, Benešová, Martina, Cohrs, Susan, Boss, Silvan D, Ametamey, Simon M, Schibli, Roger, Müller, Cristina
• Format: Journal Article
• Language: English
• Published: United States Society of Nuclear Medicine 01.10.2021
• Subjects: Accumulation; Affinity; Autoradiography; Basic Science Investigation; Binding; Biodistribution; Cancer; Cancer therapies; Computed tomography; Fluorine isotopes; Folic acid; Inflammation; Injection; Isomers; Medical imaging; Patients; Positron emission; Radioactive tracers; Receptors; Selectivity; Tissues; Tomography; Vitamin B; Xenografts; Xenotransplantation; 5-MTHF; FRα selectivity; folate receptor (FR); PET; 18F
• ISSN: 0161-5505; 1535-5667; 1535-5667; 2159-662X
• DOI: 10.2967/jnumed.120.255760

The aim of this study was to identify a folate receptor-α (FRα)-selective PET agent potentially suitable for the selection of patients who might profit from FRα-targeted therapies. The 6 and 6 isomers of F-aza-5-methyltetrahydrofolate (MTHF) were assessed regarding their binding to FRα and FRβ, expressed on cancer and inflammatory cells, respectively, and compared with F-AzaFol, the folic acid-based analog. FR selectivity was investigated using FRα-transfected (RT16) and FRβ-transfected (D4) CHO cells. The cell uptake of F-folate tracers was investigated, and receptor-binding affinities were determined with the nonradioactive analogs. In vitro autoradiography of the F-folate tracers was performed using RT16 and D4 tissue sections. Biodistribution studies and PET/CT imaging of the radiotracers were performed on mice bearing RT16 and D4 xenografts. The uptake of F-6 -aza-5-MTHF was high when using RT16 cells (62% ± 10% of added activity) but much lower when using D4 cells (5% ± 2%). The FRα selectivity of F-6 -aza-5-MTHF was further demonstrated by its approximately 43-fold higher binding affinity to FRα (half-maximal inhibitory concentration [IC ], 1.8 ± 0.1 nM) than to FRβ (IC , 77 ± 27 nM). The uptake of F-6 -aza-5-MTHF and F-AzaFol was equal in both cell lines (52%-70%), with similar affinities to FRα (IC , 2.1 ± 0.4 nM and 0.6 ± 0.3 nM, respectively) and FRβ (0.8 ± 0.2 nM and 0.3 ± 0.1 nM, respectively). The autoradiography signal obtained with F-6 -aza-5-MTHF was 11-fold more intense for RT16 than for D4 tissue sections. Biodistribution data showed high uptake of F-6 -aza-5-MTHF in RT16 xenografts (81% ± 20% injected activity per gram [IA]/g 1 h after injection) but significantly lower accumulation in D4 xenografts (7.3% ± 2.1% IA/g 1 h after injection), which was also visualized using PET. The uptake of F-6 -aza-5-MTHF and F-AzaFol was similar in RT16 (53% ± 10% IA/g and 45% ± 2% IA/g, respectively) and D4 xenografts (77% ± 10% IA/g and 52% ± 7% IA/g, respectively). This study demonstrated FRα selectivity for F-6 -aza-5-MTHF but not for F-6 -aza-5-MTHF or F-AzaFol. This characteristic, together with its favorable tissue distribution, makes F-6 -aza-5-MTHF attractive for clinical translation to enable detection of FRα-positive cancer while preventing undesired accumulation in FRβ-expressing inflammatory cells.